Rectovaginal Fistula Market Research Report – Global Forecast till 2027

Global Rectovaginal Fistula Market Research Report: by Diagnosis (Physical Exam, Contrast Tests, Blue Dye Test, Computerized Tomography (CT) Scan) By Treatment (Medications, Surgery) By End User (Hospitals & Clinics, Diagnostic Centers) - Forecast Till 2027

ID: MRFR/HC/5672-HCR | February 2021 | Region: Global | 90 pages

Please note that the assessment period of report has been updated from 2018-2023 to 2020-2027. Cordially fill the sample form for updated data.

Market Scenario

Global rectovaginal fistula market is expected to grow significantly over the forecast period. The market held a market value of USD 950 million in 2017 and is projected to grow at a CAGR of 5.4% over the forecast period. Rectovaginal fistula is abnormal connection between lower portion of large intestine- rectum-vagina. There are various causes of rectovaginal fistula such as Crohn's disease, cancer or radiation treatment in pelvic area, surgery involving vagina, perineum, rectum or anus, injuries during childbirth, and others.

The factors such as increasing prevalence pelvic cancer, Crohn’s disease is the major driving factors for the market. Moreover, increasing adoption of personalized medicine, as personalised medicine has many applications in cancer treatment. Furthermore, growing diagnosis methods for rectovaginal fistula will boost the market growth during forecast period.

However, high cost of the surgery may hamper the growth of the market during the forecast period.

According to National Cancer Institute, in 2018, an estimated 1,735,350 new cases of cancer were diagnosed in the United States and 609,640 people may die from the disease.

Segmentation

The global rectovaginal fistula market has been segmented into diagnosis, treatment, and end user.

By diagnosis, the market has been segmented into physical exam, contrast tests, blue dye test, computerized tomography (CT) scan, magnetic resonance imaging (MRI), anorectal ultrasound, anorectal manometry, and others.

Based on treatment, the market has been segmented into medications and surgery. Medications is further segmented into antibiotics and infliximab. Surgery is further segmented into sewing an anal fistula plug or patch of biologic tissue into the fistula, using a tissue graft, repairing the anal sphincter muscles, performing a colostomy before repairing a fistula in complex or recurrent cases.

The rectovaginal fistula market, by end user, has been segmented into hospitals & clinics, diagnostic centres, academic institutions and research organizations, and others.

The global rectovaginal fistula market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The rectovaginal fistula market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.

The European rectovaginal fistula market has been segmented into Western Europe and Eastern Europe. The Western Europe rectovaginal fistula market has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.

The rectovaginal fistula market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The rectovaginal fistula market in the Middle East & Africa has been segmented into the Middle East and Africa.

Key players

Cook Medical, Takeda Pharmaceutical Company, Johnson & Johnson Services Inc., Pfizer Inc., Allergan, AbbVie Inc, Novartis International AG, Bayer AG, Bristol-Myers Squibb, Boehringer Ingelheim GmbH, F. Hoffmann-La Roche, Eli Lilly and Company, GlaxoSmithKline plc, Sanofi S.A are some of the prominent players in the global rectovaginal fistula market.

Regional Market Summary

Global Rectovaginal Fistula Share (%), by Region, 2017

Source: White Papers, Company Presentations, Annual Reports

Geographically, the Americas is anticipated to dominate the global rectovaginal fistula market owing to the high domestic income, and presence of major market players. Moreover, increasing patient population in US. According to American Cancer Society, the overall estimate of 1,735,350 cases for 2018 equals more than 4,700 new cancer diagnoses each day.

Europe is expected to hold the second largest position in the global rectovaginal fistula market. The market growth in this region is attributed to the presence of strong academic & research base and availability of funding for research in the European countries. For instance, the European Research Council (ERC) provides grants for technological and scientific research conducted within the European Union (EU).

The rectovaginal fistula market in Asia-Pacific region consists of countries namely China, Japan, Republic of Korea, India, Australia and Rest of Asia-Pacific. The Asia-Pacific region is expected to be fastest growing region owing to increasing government focus on biotechnology and pharmaceutical sector and growing number of target population in the region.

The Middle East & Africa has the lowest share of the global rectovaginal fistula market. Majority of the market of the region is anticipated to be held by the Middle East region owing to the growing government initiatives for the healthcare sector.

Global Rectovaginal Fistula Market, by Diagnosis:

Physical Exam

Contrast Tests

Blue Dye Test

Computerized Tomography (CT) Scan

Magnetic Resonance Imaging (MRI)

Anorectal Ultrasound

Anorectal Manometry

Others

Global Rectovaginal Fistula Market, by Treatment:

Medications
- Antibiotics
- Infliximab

Surgery
- Sewing an Anal Fistula Plug or Patch of Biologic Tissue into the Fistula
- Using a Tissue Graft
- Repairing the Anal Sphincter Muscles
- Performing a Colostomy before Repairing a Fistula in Complex or Recurrent Cases

Global Rectovaginal Fistula Market, by End User:

Hospitals & Clinics

Diagnostic Centers

Academic Institutions and Research Organizations

Others

Global Rectovaginal Fistula Market, by Region:

Americas
- North America
  - US
  - Canada
- Latin America

Europe
- Western Europe
  - Germany
  - France
  - Italy
  - Spain
  - UK
  - Rest of Western Europe
- Eastern Europe

Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific

The Middle East & Africa
- Middle East
- Africa

Global Rectovaginal Fistula Market, by Key Players:

Cook Medical

Takeda Pharmaceutical Company

Johnson & Johnson Services Inc.

Pfizer Inc.

Allergan

AbbVie Inc

Novartis International AG

Bayer AG

Bristol-Myers Squibb

Boehringer Ingelheim GmbH

Hoffmann-La Roche

Eli Lilly and Company

GlaxoSmithKline plc

Sanofi S.A

Others

Intended Audience:

Pharmaceutical and Biotechnological Companies

Contract Research Organizations

Academic and Research Institutes

Government Associations

Table of Contents:

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary Research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restraints

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Treatment Trends & Assessment

Chapter 5. Market Factor Analysis

5.1 Porter’s Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

Chapter 6. Global Rectovaginal Fistula Market, by Diagnosis

6.1 Introduction

6.2 Physical Exam

Market Estimates & Forecast, by Region, 2020-2027